Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
NCT03208296 · Ascend Biopharmaceuticals Ltd · PHASE1/PHASE2 · suspended · last registry update 2023-02-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study did not start. Another protocol is being developed. Recruitment on hold.” | – | Registry record, Ascend Biopharmaceuticals Ltd |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-02Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06238817)
- 2024-01-30Results posted on the registry: Celgene, FEDRATINIB + Best Available Therapy (BAT) (NCT03952039)
- 2024-01-29Phase 3 first posted: Takeda, Vedolizumab + Upadacitinib (NCT06227910)
- 2023-12-15Phase 3 first posted: Zhejiang University, Prednisone+Tofacitinib + Prednisone (NCT06172361)
- 2023-12-08Phase 3 first posted: Pfizer, Ritlecitinib + Ritlecitinib 100 mg (NCT06163326)
- 2023-12-07Results posted on the registry: Incyte Corporation, Ruxolitinib cream + Vehicle Cream (NCT04896385)
- 2023-11-07Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06118411)
- 2023-10-17Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Ruxolitinib (NCT03722407)
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
- 2023-10-10Phase 3 first posted: Pfizer, Ritlecitinib + Ritlecitinib (NCT06072183)
- 2023-08-31Phase 3 first posted: Hangzhou Highlightll Pharmaceutical Co., Ltd, TLL-018 + Tofacitinib (NCT06020144)
- 2023-08-25Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06012240)
- 2023-08-22Phase 3 first posted: LEO Pharma, Delgocitinib (NCT06004050)
- 2023-07-19Results posted on the registry: Incyte Corporation, ruxolitinib + Vehicle (NCT04530344)
- 2023-06-05Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT05889182)
- 2023-05-06Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT05843643)
- 2023-04-18Phase 3 first posted: AbbVie, Upadacitinib + Adalimumab (NCT05814627)
- 2023-03-27Phase 3 first posted: Alfasigma S.p.A., Filgotinib + Placebo (NCT05785611)
- 2023-03-24Phase 3 first posted: AbbVie, Upadacitinib (NCT05782907)
- 2023-03-10Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT05764161)
- 2023-03-06Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT05755438)
- 2022-12-28Results posted on the registry: Pfizer, PF-06651600 + Placebo (NCT04517864)
- 2022-11-08Phase 3 first posted: AbbVie, Upadacitinib + Tocilizumab (NCT05609630)
- 2022-10-17Phase 3 first posted: Pfizer, Ritlecitinib + Placebo (NCT05583526)
- 2022-09-21Results posted on the registry: AbbVie, Upadacitinib + Placebo (NCT04169373)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision